These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11737346)

  • 21. A new approach to initial antiretroviral therapy: protease-sparing combination regimens.
    Hanna L
    BETA; 1998 Oct; ():9-13. PubMed ID: 11365999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Buffalo hump: what the experts suggest.
    Piliero PJ; McComsey GA
    AIDS Clin Care; 2004 Mar; 16(3):22-3. PubMed ID: 15119294
    [No Abstract]   [Full Text] [Related]  

  • 23. Precipitous declines in hemoglobin levels associated with combination zidovudine and lamivudine therapy.
    Tseng A; Conly J; Fletcher D; Keystone D; Salit I; Walmsley S
    Clin Infect Dis; 1998 Oct; 27(4):908-9. PubMed ID: 9798060
    [No Abstract]   [Full Text] [Related]  

  • 24. Anti-HIV agents. A second study confirms fat loss issues with efavirenz.
    TreatmentUpdate; 2007 Feb; 19(2):6-7. PubMed ID: 17447314
    [No Abstract]   [Full Text] [Related]  

  • 25. Hypersensitivity syndrome associated with efavirenz therapy.
    Bossi P; Colin D; Bricaire F; Caumes E
    Clin Infect Dis; 2000 Jan; 30(1):227-8. PubMed ID: 10619772
    [No Abstract]   [Full Text] [Related]  

  • 26. Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months.
    Boothby M; McGee KC; Tomlinson JW; Gathercole LL; McTernan PG; Shojaee-Moradie F; Umpleby AM; Nightingale P; Shahmanesh M
    Antivir Ther; 2009; 14(8):1089-100. PubMed ID: 20032539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Valuable combination partner. Great benefit for therapy naive patients].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():82-4. PubMed ID: 15373061
    [No Abstract]   [Full Text] [Related]  

  • 28. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
    DeJesus E; McCarty D; Farthing CF; Shortino DD; Grinsztejn B; Thomas DA; Schrader SR; Castillo SA; Sension MG; Gough K; Madison SJ;
    Clin Infect Dis; 2004 Aug; 39(3):411-8. PubMed ID: 15307010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efavirenz-induced catatonia.
    Sabato S; Wesselingh S; Fuller A; Ray J; Mijch A
    AIDS; 2002 Sep; 16(13):1841-2. PubMed ID: 12218403
    [No Abstract]   [Full Text] [Related]  

  • 30. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Aurpibul L; Puthanakit T; Lee B; Mangklabruks A; Sirisanthana T; Sirisanthana V
    Antivir Ther; 2007; 12(8):1247-54. PubMed ID: 18240864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipodystrophy and long-term therapy with nucleoside reverse transcriptase inhibitors.
    Moreno S; Martínez E
    AIDS; 2000 May; 14(7):905-6. PubMed ID: 10839605
    [No Abstract]   [Full Text] [Related]  

  • 32. CT appearances of HIV-related lipodystrophy syndrome.
    Gellett LR; Haddon L; Maskell GF
    Br J Radiol; 2001 Apr; 74(880):382-3. PubMed ID: 11387159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-HIV agents. Efavirenz and fat wasting--what might be happening?
    TreatmentUpdate; 2007 Feb; 19(2):7-8. PubMed ID: 17447315
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical trials group: two studies are now open to patients who qualify.
    Craig K
    HIV Clin; 2000; 12(1):5. PubMed ID: 11810862
    [No Abstract]   [Full Text] [Related]  

  • 35. Triple-nucleoside regimens versus efavirenz.
    Maida I; Nuñez M; Soriano V
    N Engl J Med; 2004 Aug; 351(7):717-9; author reply 717-9. PubMed ID: 15309748
    [No Abstract]   [Full Text] [Related]  

  • 36. Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
    Nolan D
    Drug Saf; 2005; 28(12):1069-74. PubMed ID: 16329710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efavirenz in HIV infection.
    Casado JL; Moreno S
    N Engl J Med; 2000 Apr; 342(17):1290-1. PubMed ID: 10787332
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy.
    Martínez E; García-Viejo MA; Blanco JL; Bianchi L; Buira E; Conget I; Casamitjana R; Mallolas J; Gatell JM
    Clin Infect Dis; 2000 Nov; 31(5):1266-73. PubMed ID: 11073762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
    Dai Z; Cai W; Hu F; Lan Y; Li L; Chung C; Caughey B; Zhang K; Tang X
    Curr Mol Med; 2015; 15(10):975-9. PubMed ID: 26592244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [3 years' data of tenofovir. Confirmed as a valuable building block].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():30-1. PubMed ID: 15373042
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.